Alterity Therapeutics Limited (PRNAF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 3.8 Million AUD | -0.24% |
| 2023 | 3.81 Million AUD | -24.76% |
| 2022 | 5.06 Million AUD | 18.88% |
| 2021 | 4.26 Million AUD | 3892.89% |
| 2020 | -112.42 Thousand AUD | -242.6% |
| 2019 | 78.84 Thousand AUD | -56.05% |
| 2018 | 179.37 Thousand AUD | 61.5% |
| 2017 | 111.06 Thousand AUD | -7.33% |
| 2016 | 119.84 Thousand AUD | 248.96% |
| 2015 | -80.45 Thousand AUD | -100.98% |
| 2014 | 8.2 Million AUD | 82.89% |
| 2013 | 4.48 Million AUD | 2304.6% |
| 2012 | 186.66 Thousand AUD | 176.78% |
| 2011 | -243.1 Thousand AUD | -213.07% |
| 2010 | 215 Thousand AUD | -49.79% |
| 2009 | 428.19 Thousand AUD | -12.97% |
| 2008 | 491.99 Thousand AUD | -2.97% |
| 2007 | 507.04 Thousand AUD | -33.5% |
| 2006 | 762.48 Thousand AUD | -71.14% |
| 2005 | 2.64 Million AUD | 14.53% |
| 2004 | 2.3 Million AUD | 27.39% |
| 2003 | 1.81 Million AUD | 127.98% |
| 2002 | 794.39 Thousand AUD | 53.9% |
| 2001 | 516.18 Thousand AUD | 555.4% |
| 2000 | 78.75 Thousand AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 876.44 Thousand AUD | -2.82% |
| 2024 Q1 | 901.87 Thousand AUD | 26.49% |
| 2024 FY | -147.52 Thousand AUD | -103.87% |
| 2024 Q4 | 985.66 Thousand AUD | 0.0% |
| 2024 Q3 | 1 Million AUD | 14.17% |
| 2023 Q4 | 712.98 Thousand AUD | 1.46% |
| 2023 Q3 | 702.73 Thousand AUD | -38.51% |
| 2023 FY | 3.81 Million AUD | -24.76% |
| 2023 Q1 | 1.11 Million AUD | -18.14% |
| 2023 Q2 | 1.14 Million AUD | 2.7% |
| 2022 Q2 | 1.14 Million AUD | 6.63% |
| 2022 Q4 | 1.35 Million AUD | 4.35% |
| 2022 Q3 | 1.3 Million AUD | 13.48% |
| 2022 Q1 | 1.07 Million AUD | -9.4% |
| 2022 FY | 5.06 Million AUD | 18.88% |
| 2021 Q1 | 861.51 Thousand AUD | 187.66% |
| 2021 Q3 | 1.12 Million AUD | 24.53% |
| 2021 FY | 4.26 Million AUD | 3892.89% |
| 2021 Q4 | 1.18 Million AUD | 5.33% |
| 2021 Q2 | 906.03 Thousand AUD | 5.17% |
| 2020 FY | -112.42 Thousand AUD | -242.6% |
| 2020 Q4 | -982.79 Thousand AUD | 6.66% |
| 2020 Q1 | 876.47 Thousand AUD | -29.73% |
| 2020 Q2 | 870.36 Thousand AUD | -0.7% |
| 2020 Q3 | -1.05 Million AUD | -220.98% |
| 2019 Q3 | 1.14 Million AUD | -2.5% |
| 2019 Q4 | 1.24 Million AUD | 9.16% |
| 2019 FY | 78.84 Thousand AUD | -56.05% |
| 2019 Q2 | 1.17 Million AUD | 0.0% |
| 2019 Q1 | 1.17 Million AUD | 53.32% |
| 2018 FY | 179.37 Thousand AUD | 61.5% |
| 2018 Q1 | 686.23 Thousand AUD | 22.76% |
| 2018 Q4 | 764.36 Thousand AUD | 0.0% |
| 2018 Q3 | 764.36 Thousand AUD | 11.39% |
| 2018 Q2 | 686.23 Thousand AUD | 0.0% |
| 2017 Q2 | 897.6 Thousand AUD | -0.0% |
| 2017 FY | 111.06 Thousand AUD | -7.33% |
| 2017 Q4 | 558.98 Thousand AUD | 0.0% |
| 2017 Q3 | 558.98 Thousand AUD | -37.73% |
| 2017 Q1 | 897.6 Thousand AUD | -6.39% |
| 2016 Q3 | 958.92 Thousand AUD | -29.92% |
| 2016 Q2 | 1.36 Million AUD | 0.0% |
| 2016 Q1 | 1.36 Million AUD | -6.26% |
| 2016 Q4 | 958.92 Thousand AUD | 0.0% |
| 2016 FY | 119.84 Thousand AUD | 248.96% |
| 2015 FY | -80.45 Thousand AUD | -100.98% |
| 2015 Q3 | 1.45 Million AUD | -12.01% |
| 2015 Q4 | 1.45 Million AUD | 0.0% |
| 2015 Q2 | 1.65 Million AUD | 0.0% |
| 2015 Q1 | 1.65 Million AUD | -47.32% |
| 2014 Q2 | 717.22 Thousand AUD | 0.0% |
| 2014 Q4 | 3.14 Million AUD | 0.0% |
| 2014 FY | 8.2 Million AUD | 82.89% |
| 2014 Q3 | 3.14 Million AUD | 339.03% |
| 2014 Q1 | 717.22 Thousand AUD | -34.33% |
| 2013 Q3 | 1.09 Million AUD | 0.0% |
| 2013 FY | 4.48 Million AUD | 2304.6% |
| 2013 Q4 | 1.09 Million AUD | 0.0% |
| 2012 FY | 186.66 Thousand AUD | 176.78% |
| 2011 FY | -243.1 Thousand AUD | -213.07% |
| 2010 FY | 215 Thousand AUD | -49.79% |
| 2009 FY | 428.19 Thousand AUD | -12.97% |
| 2008 Q2 | 126.96 Thousand AUD | -0.04% |
| 2008 FY | 491.99 Thousand AUD | -2.97% |
| 2008 Q4 | 119.15 Thousand AUD | 0.41% |
| 2008 Q3 | 118.66 Thousand AUD | -6.53% |
| 2008 Q1 | 127 Thousand AUD | -5.83% |
| 2007 FY | 507.04 Thousand AUD | -33.5% |
| 2007 Q4 | 134.86 Thousand AUD | -0.25% |
| 2007 Q3 | 135.2 Thousand AUD | 14.02% |
| 2007 Q2 | 118.58 Thousand AUD | 0.23% |
| 2007 Q1 | 118.3 Thousand AUD | -37.88% |
| 2006 Q2 | 217.31 Thousand AUD | 0.01% |
| 2006 Q1 | 217.29 Thousand AUD | -65.01% |
| 2006 Q3 | 190.67 Thousand AUD | -12.25% |
| 2006 Q4 | 190.44 Thousand AUD | -0.12% |
| 2006 FY | 762.48 Thousand AUD | -71.14% |
| 2005 Q2 | 685.06 Thousand AUD | 0.1% |
| 2005 FY | 2.64 Million AUD | 14.53% |
| 2005 Q1 | 684.35 Thousand AUD | 13.98% |
| 2005 Q4 | 621.08 Thousand AUD | -2.5% |
| 2005 Q3 | 637 Thousand AUD | -7.02% |
| 2004 Q4 | 600.43 Thousand AUD | -0.66% |
| 2004 FY | 2.3 Million AUD | 27.39% |
| 2004 Q1 | 561.87 Thousand AUD | -29.88% |
| 2004 Q2 | 561.68 Thousand AUD | -0.03% |
| 2004 Q3 | 604.41 Thousand AUD | 7.61% |
| 2003 FY | 1.81 Million AUD | 127.98% |
| 2003 Q2 | 263.42 Thousand AUD | 8.67% |
| 2003 Q1 | 242.4 Thousand AUD | 0.0% |
| 2003 Q3 | 574.13 Thousand AUD | 117.96% |
| 2003 Q4 | 801.31 Thousand AUD | 39.57% |
| 2002 FY | 794.39 Thousand AUD | 53.9% |
| 2001 FY | 516.18 Thousand AUD | 555.4% |
| 2000 FY | 78.75 Thousand AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 11.7 Million USD | 67.495% |
| Arch Therapeutics, Inc. | -2439.00 USD | 156105.781% |
| CSL Limited | 7.56 Billion USD | 99.95% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 96.805% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2055.064% |
| BioStem Technologies, Inc. | 15.42 Million USD | 75.332% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 60.41% |
| Qrons Inc. | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 1290.891% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 114.749% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -5335.687% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 3162.334% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 7984.5% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -2608.172% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.071% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 74.632% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -122562.186% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 61.15% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -5688.98% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 11241.965% |
| Mesoblast Limited | -35.16 Million USD | 110.819% |
| Marizyme, Inc. | 457.7 Thousand USD | -731.323% |
| Genus plc | 178.7 Million USD | 97.871% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 98.271% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -6014.777% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -827.671% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 34690.736% |
| ContraFect Corporation | -154 Thousand USD | 2570.767% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 7709.962% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -4856.92% |
| IMV Inc. | -962.29 Thousand USD | 495.406% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 1081.928% |
| MultiCell Technologies, Inc. | 49.32 USD | -7714784.428% |
| ONE Bio Corp. | 20.12 Million USD | 81.094% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 90.55% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -7681.147% |
| Q BioMed Inc. | -8988.00 USD | 42434.012% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 86.533% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 24769.223% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 91.422% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 433.311% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 76937.258% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 4001.944% |
| GB Sciences, Inc. | -624.00 USD | 609872.596% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 4522.956% |
| HST Global, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 1829417.788% |
| Enzolytics Inc. | 30.7 Thousand USD | -12290.846% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -688.707% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.657% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 839.535% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -516.307% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 43065.007% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 4637.897% |
| Kadimastem Ltd | -630.13 Thousand USD | 703.833% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -285.127% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 32250.241% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -2055.064% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -180.367% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 13220.624% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -745.471% |
| SYBLEU INC | 11.69 Thousand USD | -32432.327% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 17.427% |
| Bioxytran, Inc. | -8285.00 USD | 46026.144% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 1120.102% |
| Neutra Corp. | 14.33 Thousand USD | -26443.293% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 4740.221% |
| PureTech Health plc | -1.6 Million USD | 337.366% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 480.028% |
| IXICO plc | 3.27 Million USD | -16.36% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 648.268% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 312.45% |
| CSL Limited | 7.7 Billion USD | 99.951% |
| Cellectis S.A. | 18 Thousand USD | -21038.783% |